European Archives - Page 372 of 1054 - European Medical Journal

World AIDS Day 2022 special

Helena and Isabel share a very special episode to mark World AIDS Day, featuring Dr Nneka Nwokolo, Global Head of Patient Affairs at ViiV.

DOACs in Review - How did we get here?

This upcoming webinar discussion shares clinical insights from an expert in the use of direct oral anticoagulants for the treatment of…

Proactive Risk Management: A Novel Approach to Embedding Oral Corticosteroid Stewardship into Asthma Care

The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoing overreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population.

EMJ Respiratory 10 [Supplement 2] 2022

The continued inclusion of oral corticosteroids (OCS) in treatment guidelines, as well as the accessibility, familiarity, and relatively low cost of this therapeutic option compared with newer alternatives, has contributed to an ongoing overreliance on OCS treatments in severe asthma. This overuse continues despite accumulating evidence to demonstrate the detrimental long-term effects associated with even a short-term, low-dose course of OCS in this patient population.

Dilemmas in breast cancer treatment planning: how understanding tumor biology with MammaPrint and BluePrint can help you

This webinar will educate you on how the biology of a breast tumour reveals additional information that can support choosing the best treatment plan. It will specifically focus on now-a-days clinical dilemmas, like what is the best treatment for pre-menopausal patients, what is the optimal duration of endocrine therapy and how can I find those nasty tumours. The dilemmas are discussed with the help of cases.

Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study

As part of the 31st European Academy of Dermatology and Venereology (EADV) Annual Congress held in Milan, Italy, and online, 7th–10th September 2022, five poster presentations outlined results from the Phase IIb study of remibrutinib (LOU064) in patients with chronic spontaneous urticaria inadequately controlled with H1-antihistamines.

Difficult-to-Treat: Treating Symptoms Not Numbers

Nebojsa Skrepnik joins Jonathan Sackier on this episode of the EMJ Podcast to discuss opening a clinical research centre and platelet-rich plasma treatments.

EMJ Nephrology 10 [Infographic 3] 2022

This infographic explores a contemporary strategy to decrease the risk of cardiovascular disease and mortality associated with end-stage kidney disease (ESKD).

EMJ

Infographic: Improving Outcomes in Haemodialysis: A New Look at an Old Issue

This infographic explores a contemporary strategy to decrease the risk of cardiovascular disease and mortality associated with end-stage kidney disease (ESKD).

Optimising Antimicrobial Stewardship to Tackle Clostridioides difficile Infection and Improve Patient Outcomes

Clostridioides difficile, formerly known as Clostridium difficile, is a Gram-positive spore-forming and toxin-producing bacterium that causes diarrhoea in vulnerable patient groups. It is a common hospital-acquired infection but also occurs in the community.